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Abstract. The resolution of advanced liver fibrosis has been recently recognized to be possible, if the
causative stimuli are successfully removed. However, whether complete resolution from cirrhosis, the
end stage of liver fibrosis, can be achieved is still questionable. Delivery of interstitial collagenases, such
as matrix metalloproteinase (MMP)-1, in the liver could be an attractive strategy to treat advanced
hepatic fibrosis from the view point that the imbalance between too few interstitial collagenases and too
many of their inhibitors is the main obstacle to the resolution from fibrosis. Remodeling of hepatic
extracellular matrix by delivered interstitial collagenases also facilitates the disappearance of activated
hepatic stellate cells, the main matrix-producing cells in the liver, and promotes the proliferation of
hepatocytes. This review will focus on the impact of the gene delivery of MMPs for the treatment of
advanced liver fibrosis while discussing other current therapeutic strategies for liver fibrosis, and on the
need for the development of a safe and effective delivery system of MMPs.
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INTRODUCTION
Liver fibrosis results from continuous damage to the
liver, including viral hepatitis, alcohol abuse, drugs, metabol-
ic diseases involving an overload of iron or copper, autoim-
mune diseases, or congenital abnormalities (1,2). The end
stage of liver fibrosis, cirrhosis, is characterized by increased
deposition and altered composition of the ECM and the
appearance of regenerative nodules (3,4), accompanied by
hepatic failure and portal hypertension (5). This represents
an enormous worldwide healthcare problem.
From a treatment viewpoint, several approaches have
successfully prevented the progression of liver fibrosis in
animal models. However, because fibrotic liver disease may
not present clinically until an advanced or cirrhotic stage, the
possibility of reversing established fibrosis is an essential
issue. Advanced hepatic fibrosis had been believed to be a
passive and irreversible process due to the collapse of the
hepatic parenchyma and its substitution with collagen-rich
tissue (6). Recently, however, it is thought that hepatic
fibrosis may be reversible if the underlying injurious stimuli
are removed. Indeed, some investigators have reported
improvement in liver fibrosis and cirrhosis in selective
patients with effective antiviral therapies in chronic viral
hepatitis (7,8) and with surgical decompression of secondary
biliary fibrosis (9), suggesting a capacity for recovery even
from established cirrhosis. Transplantation is another effec-
tive treatment for advanced cirrhosis (10,11) but is limited by
the number of available donor organs. Therefore, effective
antifibrotic treatments for established liver fibrosis are
earnestly required, and biotechnology and pharmaceutical
companies are increasingly interested in developing new
antifibrotic therapies.
PATHOGENESIS OF LIVER FIBROSIS
Liver fibrosis is associated with major alterations in both
the quantity and composition of the extracellular matrix
(ECM) (3,4). Accumulation of ECM, including fibrillar
collagens, fibronectin, laminin, hyaluronan, and proteogly-
cans, results from both increased synthesis and decreased
degradation (12).
Hepatic stellate cells (HSC) are believed to be the main
ECM-producing cells in the injured liver (1), while portal
fibroblasts also play important roles in several kinds of liver
fibrosis (13,14). In the normal liver, HSC reside in the space
of Disse and are the major storage sites of vitamin A. In
injured areas of the liver, HSC activate or transdifferentiate
into myofibroblast-like cells, expressing contractile proteins
and secreting large amounts of ECM, especially fibrillar
collagens (type I and type III) (15,16). Many researchers are
now investigating the mechanisms mediating the activation of
HSC, and activated nonparenchymal cells (NPC), such as
Kupffer cells, are believed to play important roles in the
mechanism (17,18).
The decreased activity of ECM-removing MMPs is
mainly due to an increased expression of their specific
inhibitors, tissue inhibitors of metalloproteinase (TIMPs).
The key enzymes in the degradation of fibrillar collagens are
matrix metalloproteinase (MMP)-1 in humans and MMP-13
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sion of MMP-1 or MMP-13 is very limited, whereas that of
MMP-2 increases (21,22). On the other hand, fibrotic livers
have high expression of the TIMPs, including TIMP-1 and
TIMP-2 (23–25). Thus, there is a combination of low expres-
sion of interstitial collagenases and high TIMPs that prevents
the degradation of the fibrillar collagens. Moreover, it has
been recently well documented that fibrillar collagens act as a
survival factor for activated HSC. An in vitro study has shown
that HSC are activated on collagen type I, whereas they are
quiescent on Matrigel (26), implying that signals from the
ECM through some types of adhesion molecules, such as
integrins, play critical roles in HSC activation. TIMPs are also
reported to block HSC apoptosis in fibrotic livers (27,28).
Thus, the imbalance between too few MMPs, too much ECM
and too many TIMPs possibly account for the advanced liver
fibrosis and the failure to resolve the fibrous scar (Fig. 1).
RESOLUTION OF LIVER FIBROSIS
Recently, many researchers have focused on the reversal
of hepatic fibrosis (29,30). As mentioned above, recent
evidence indicates that even advanced fibrosis is reversible,
in contrast with the traditional view that cirrhosis is an
irreversible disease (6). Increased collagenolytic activity is a
major mechanism of fibrosis resolution (31), and fibrillar
collagens (type I and III) are degraded by interstitial MMPs.
According to several animal models of liver fibrosis resolu-
tion, the expression of TIMPs rapidly decreases while
interstitial MMPs continue to be expressed during the
resolution, resulting in increased MMP activity and conse-
quent matrix degradation within the liver (27,29,30).
Together with these changes in MMP activity, the
apoptosis of activated HSC has been observed in the
resolution process of hepatic fibrosis (29,32,33). In a progres-
sive fibrogenic process, activated HSC secrete large amounts
of ECM. When the injurious stimulus is withdrawn and the
survival factors for activated HSC, including soluble factors
and ECM, are partially removed, the loss of activated HSC
by apoptosis is thought to occur. HSC apoptosis, in turn,
facilitates the remodeling process by removing the major
cellular source of collagen and TIMPs.
However, it is still questionable whether the complete
resolution of advanced liver fibrosis is possible. Data from
animal experiments indicate that resolution from an exten-
sive micronodular to an attenuated macronodular cirrhosis is
possible when injurious stimuli are removed, while complete
resolution is limited by ECM cross-linking and a failure of
activated HSC to undergo apoptosis (30). Therefore, it seems
that treatments possessing MMP activity against matrix-cross
linking are necessary for complete, or nearly complete,
histologic resolution from advanced cirrhosis.
Hepatocytes
Hepatic stellate
cells
Macrophages
Sinusoidal 
endothelial cells
Apoptotic 
hepatocytes
Activated 
hepatic stellate
cells
Matrix
Fig. 1. Azan-Mallory staining of human samples from normal (top) and cirrhotic (bottom) livers. Blue-stained area represents collagen and
reticular fibers. Regenerative nodules surrounded by abundant fibrous band are observed in the cirrhotic liver (bottom). Schematic changes in
the hepatic architecture between normal (right top) and cirrhotic (right bottom) livers are also shown.
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IN TREATMENT OF LIVER FIBROSIS
Removal of the underlying stimulus is believed to be the
most effective strategy for the treatment of hepatic fibrosis.
Meanwhile, alternative approaches to treat this disease at
earlier stages are currently in progress in consideration of the
mechanism of liver fibrosis and its resolution (Table I).
Anti-inflammatory Approaches
Hepatic inflammation invariably precedes fibrosis as men-
tioned above. Consequently, a number of anti-inflammatory
agents have been evaluated intensively. Corticosteroids have
been used to successfully treat autoimmune hepatitis, and also
showntoimprove survivalandreducedprogressiontocirrhosisin
selected patients with severe alcoholic hepatitis (34)w i t hn o
benefit in the treatment of primary biliary cirrhosis (PBC) (35).
Colchicine, a well-known anti-inflammatory plant extract, has
been used as an antifibrotic agent on the basis of a beneficial
effect in experimental fibrosis models and cirrhotic patients
(36), although there is some discrepancy between the subse-
quently reported study (37). Other anti-inflammatory agents
such as malotilate (38) and octreotide (39) have been reported
to be effective for the treatment of liver fibrosis in animal
models, but promising results with these agents in cirrhotic
patients remains obscure. Antagonism of pro-inflammatory
cytokines is also an attractive approach. An antibody against
TNFa (40)o ras o l u b l eT N F a receptor (41) has shown potential
for reducing liver injury in experimental models. However,
randomized controlled trial concerning the effect of the
humanized monoclonal anti-TNFa antibody, infliximab, in
acute alcoholic hepatitis was stopped early due to an excess of
deaths through sepsis (42). Thalidomide has also shown its
antagonistic effect against TNFa, and been shown to be bene-
ficial in experimental models of liver injury (43,44). Blockade of
IL-1, another important pro-inflammatory cytokine, using IL-1
receptor antagonist reduced liver fibrosis in an experimental
model (45). IL-10 also has potent anti-inflammatory and
antifibrotic effects. Recombinant IL-10 reduced inflammation
and fibrosis in patients with chronic hepatitis C, but increased
HCV viral burden (46).
Inhibition of HSC Activation and Proliferation
Hepatic stellate cells (HSC) are believed to be the main
ECM-producing cells in the injured liver. Therefore, inhibi-
tion of HSC activation or proliferation is critically important
in the treatment of liver fibrosis.
Many kinds of antioxidants have been investigated
because oxidative stress can induce HSC activation (47).
Vitamin E inhibited HSC activation in several experimental
models (48,49), and also in a pilot study of humans with
chronic hepatitis C infection (50). Polyenylphosphatidylcho-
line, an extract from soybean, has shown beneficial effect in
ethanol- (51) or carbon tetrachloride (CCl4)-induced (52)
experimental hepatic fibrosis. Other antioxidants, such as
silymarin (53), n-acetylcysteine (54,55), and S-adenosyl-L-
methionine (56) can inhibit HSC activation in experimental
models of liver fibrosis, but silymarin had no effect in another
controlled trial in human (57).
Table I. Therapeutic Strategies for the Treatment of Liver Fibrosis
Therapeutical Target Agent
Supress inflammation corticosteroids
colchicine
malotilate
octreotide
TNFa antagonist (e.g. anti- TNFa antibody, soluble TNFa receptor, thalidomide)
IL- 1 receptor antagonist
recombinant IL- 10
Inhibit HSC activation and proliferation antioxidants (e.g. vitamin E, phosphatidylcholine,
silymarin, n- acetylcysteine, S- adenosyl- L-methionine)
tyrosine kinase inhibitors (e.g. genistein, imatinib mesylate)
soluble dominant- negative form of the PDGF receptor
PI3K inhibitors (e.g. wortmanin, canrenone, LY294002)
Ras inhibitor S- farnesylthiosalicylate
ROCK inhibitor Y- 27632
TGF- b antagonist (e.g. camostat, soluble or dominant- negative
TGF- b type II receptors, TGFb1 antisense mRNA, smad7, HGF)
AT receptor inhibitors (e.g. losartan, candesartan, olmesartan)
ACE inhibitors (e.g., peridinopril, captopril)
Trichostatin A
Stimulate HSC apoptosis Fas ligand
NGF
gliotoxin
sulfasalazine
Enhance matrix degradation MMPs
TIMP antagonist
uPA
bone marrow transplantation
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in hepatic fibrogenesis, promoting HSC proliferation or
stimulating ECM production by HSC. Platelet-derived
growth factor (PDGF) is a powerful mitogen for HSC (58),
and its signaling pathway can be targeted for fibrosis therapy.
Inhibition of the PDGF receptor using tyrosine kinase
inhibitors such as genistein and imatinib mesylate blocked
HSC activation and proliferation in vitro or in vivo (59,60). A
soluble dominant-negative form of the PDGF receptor
showed similar results in bile duct-ligated rats (61). PI3 K, a
downstream effecter of PDGF signaling, has also been
studied as therapeutic target. Inhibitors of PI3 K such as
wortmanin, canrenone, and LY294002 suppressed HSC
migration and proliferation (62–64). The small GTPase Ras
can be activated by PDGF to lead to cellular proliferation
and migration, and the Ras inhibitor S-farnesylthiosalicylate
suppressed HSC proliferation and migration and attenuated
thioacetamide-induced liver fibrosis in rats (65). A Ras-
related GTPase, RhoA, is also implicated in HSC activation
and treatment with an inhibitor of Rho_s associated kinase
ROCK, Y-27632, blocked HSC activation and proliferation
in vivo and in vitro (66,67).
TGF-b1 is one of the most profibrogenic cytokines and is
a potent activator of HSC. Several inhibitors of the TGF-b
pathway have been effective in experimental models of liver
fibrosis. These include camostat, a serine protease inhibitor
that prevents release of latent TGF-b (68), soluble or
dominant-negative TGF-b type II receptors (69,70), adeno-
viral expression of TGF-b1 antisense mRNA (71), and gene
transfer of smad7 that blocks TGF-b intracellular signaling
(72). However, no anti-TGF-b strategy has been studied in
human. Hepatocyte growth factor (HGF) has also shown its
anti-fibrogenic effect in experimental models. Recombinant
HGF and gene therapy with HGF cDNA promoted regres-
sion of fibrosis in vivo (73,74), suppressing TGF-b expression
and up-regulating MMP activity.
Angiotensin-II (AT-II) is a vasoconstrictive cytokine in
the rennin-angiotensin system, which has been shown to be
associated with HSC activation and fibrosis (75). A variety of
angiotensin-I (AT-I) and -II receptor inhibitors such as
losartan, candesartan, and olmesartan (76–78), and inhibitors
of angiotensin-converting enzyme (57) such as peridinopril
and captopril (77,79) have also shown beneficial effects in
animal models of liver fibrosis.
Meanwhile, histone deacetylation is a key gene regu-
latory process during HSC activation. Trichostatin A, a
deacetylase inhibitor, reduced experimentally HSC acti-
vation in vitro (80).
Stimulation of HSC Apoptosis
Spontaneous resolution of liver fibrosis is associated
with apoptosis of HSC as described above, so induction of
HSC apoptosis could be make a useful anti-fibrotic therapy.
HSC express a number of cell-surface death receptors,
including Fas, TNFa receptor, and nerve growth factor
(NFG) receptor. Activation of such death receptors following
exposure to Fas ligand (81) or NGF (82) stimulated HSC
apoptosis in vitro. Nuclear factor (NF)-k B is a transcription
factor which can induce transcription of anti-apoptotic genes,
and NF-kB protects HSC from apoptosis. Thus inhibition of
NF-kB in HSC can promote HSC apoptosis. A fungal meta-
bolite gliotoxin has been shown to promote HSC apoptosis,
and it accelerated recovery from experimental liver fibrosis
(33). Another potent NF-kB inhibitor, sulfasalazine, also
increased HSC apoptosis in vitro and in vivo (83). Ras
inhibitor, S-farnesylthiosalicylate, also induced HSC apopto-
sis in TAA-induced established liver fibrosis (84).
Promotion of Matrix Degradation
Animal experiments suggest that total degradation of
fibrous scar observed in advanced liver fibrosis, cirrhosis,
could be impossible even if causative stimuli are successfully
removed (30). Therefore, some anti-fibrotic therapy targeting
the existing fibrous scar is required. Such strategies will be
discussed in detail later in this review.
Bone Marrow Transplantation as an Anti-fibrotic Therapy
Recruitment of bone marrow-derived cells (BMC) into a
variety of injured organs and differentiation of these cells
into organ specific cells has been reported in the last few
years. As for liver fibrosis, BMC has been reported to
participate in the remodeling process during fibrosis resolu-
tion, and bone marrow transplantation has proved to be an
attractive anti-fibrotic therapy (85). The molecular mecha-
nism underlying such BMC-related matrix degradation
possibly includes MMP activities (85,86). Meanwhile, there
is another aspect of BMC in liver fibrosis. Several studies
have shown that BMC also participate in fibrogenesis in the
liver (87–89), so more detailed analysis of the role of BMC in
liver fibrosis is required.
REMODELING OF EXTRACELLULAR MATRIX
BY DELIVERING INTERSTITIAL MMPS
In human studies, partial resolution of cirrhosis, such as
resolution from an extensive micronodular to an attenuated
macronodular cirrhosis, has been reported, if the fibrogenic
stimuli are successfully removed (7,90), suggesting the
current best treatment for hepatic fibrosis is the removal of
the underlying injurious causes. However, many clinicians
may feel that advanced cirrhosis cannot return to mild
fibrosis even if the ongoing fibrogenic stimuli have appeared
to resolve or diminish during their follow-up observation.
Accordingly, a more promising strategy might require other
approaches in addition to the simple removal of the
underlying causes for the treatment of advanced liver fibrosis
or cirrhosis, especially in humans.
Molecular studies of the expression of mRNA for MMPs
have shown that they are expressed in the liver even in
cirrhosis, but their activity is suppressed by powerful specific
inhibitors, TIMPs (91). Therefore, it is speculated that the
potential for matrix degradation is present even in advanced
cirrhosis. Manipulation of the imbalance between too few
interstitial collagenases and too many TIMPs may possibly
facilitate matrix degradation in fibrotic or cirrhotic livers,
resulting in the resolution of the fibrosis.
There are logically two kinds of strategy to manipulate
the imbalance between too few interstitial collagenases and
252 Iimuro and Brennertoo many TIMPs, leading to up-regulation of collagenase
activity in fibrotic livers. One possible approach is the
overexpression of interstitial MMPs in the livers, while
another possibility is the inhibition of the excessive amount
of TIMPs. In this review, the authors have focused on the
former approach.
Several types of MMPs can digest fibrillar collagens;
however, the most potent MMPs against these collagens are
collagenases including MMP-1, MMP-8, and MMP-13 (92).
Delivery of collagenases into advanced liver fibrosis has been
reported by us and others using experimental animal models
(93,94). In our experiment, a complementary DNA encoding
human pro-MMP-1 was delivered into established liver
fibrosis using an adenoviral vector in a rat model (Fig. 2a).
In that experiment, we tested our hypothesis that the
transient manipulation of the imbalance between collagen-
eses and TIMPs might attenuate established liver fibrosis
induced by long-term treatment with thioacetamide (TAA).
Long term administration of TAA has been reported to
result in a characteristic lesion in rat liver, which corresponds
to cirrhosis-like patterns of micronodular cirrhosis type.
During its development a reproducible temporal course of
biochemical and morphological changes can be recognized.
After withdrawal of the toxic agent this lesion persists for at
least 2 months (95). Western blot analysis with liver tissue
homogenates showed that the delivery of human pro-MMP-1
complementary DNA by Ad5MMP-1 (510
9 pfu per rat
intravenously) successfully expressed pro-MMP-1 in all livers
infected with Ad5MMP-1. Moreover, a significant amount of
the active form of MMP-1 (41 kilodaltons) was also detected
in this assay, indicating that the expressed pro-MMP-1
protein was gradually converted to the active form in vivo
(Fig. 2b). One week after their last TAA treatment, the rats
were infected with Ad5MMP-1 or Ad5LacZ, a control
adenovirus (510
9 pfu per rat). Histological changes in the
liver were examined at 2 and 4 weeks after the infection. The
control Ad5LacZ had no obvious effect on the established
liver fibrosis, which developed after 7 weeks of TAA
treatment (Fig. 3a). After the Ad5MMP-1 infection, the
fibrosis was significantly attenuated by 2 weeks and remained
attenuated by 4 weeks, as indicated by Masson_s trichrome
staining (Fig. 3b). Preferential target cells in the liver
following adenovirus-mediated gene transfer are generally
hepatocytes as well known. Indeed, main target cells in our
experiment were also hepatocytes (96), while human MMP-1
protein expression was observed rather diffusely because the
expressed MMP-1 was secreted out of the infected cells.
Notably, in Ad5MMP-1-infected rats, the area of a-SMA-
positive cells (a marker of activated HSC) dramatically
decreased at 2 weeks, whereas infection with Ad5LacZ had no
effect(Fig.3c, d). A significant decrease in the a-SMA-positive
area was observed only in the Ad5MMP-1-infected animals,
indicating that degradation of fibrillar collagens because of
MMP-1 overexpression in the liver can lead to a decrease in
the number of activated HSC. This phenomenon is consistent
with the hypothesis that the loss of survival factor, such as
fibrillar ECM, facilitates the disappearance, or apoptosis, of
activated HSC, which in turn leads to lower expression of
TIMPs and ECM, resulting in the resolution of liver fibrosis.
Another key observation in our study was that the
proliferation of hepatocytes was induced by MMP-1 expres-
sion in the liver. Degradation of fibrillar collagens due to
MMP-1 overexpression possibly affects the interaction be-
tween ECM and hepatocytes. Because hepatocytes are
known to be responsive to the biophysical state of ECM
(97,98), modification of their interaction possibly stimulates
ab
Human pro-MMP-1 cDNA
ProMMP-1
MMP-1
pACCMV.PLPASR (+) plasmid
Sal I Hind III 
Homologous 
recombination
Ad5MMP-1
E1-deleted adenovirus type 5 
DNA
Fig. 2. a Schema of construction of adenovirus carrying human pro-MMP-1 cDNA (Ad5MMP-1). Plasmid pRc/CMV-pro-MMP-1, which
contains a human pro-MMP-1 complementary DNA, was subcloned into the SalI/HindIII site of the pACCMV.PLPASR (+) plasmid to
construct the plasmid pACCMV/MMP-1, in which pro-MMP-1 is driven by the cytomegalovirus promoter/enhancer. The recombinant
adenovirus was then constructed by cotransfection of the 293 embryonic human kidney cell line with the pACCMV/MMP-1 plasmid plus the
purified fragment of ClaI-digested DNA from E1-deleted adenovirus type 5 (Ad5). b Western blotting for human pro-MMP-1 and MMP-1
using liver homogenate obtained from rats infected with Ad5MMP-1.
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in our model that several growth factors bound to hepatic
ECM, such as hepatocyte growth factor (99), are freed from
ECM by MMP-1 overexpression and that the activated
growth factors facilitate hepatocyte proliferation. Indeed,
this proliferative response of hepatocytes is not specific to the
fibrotic liver, because we have observed the same prolifera-
tive effect of MMP-1 on hepatocytes when MMP-1 was
expressed in normal rat livers (96).
ECM-cross linking has been implicated in the mecha-
nism for the limited resolution of advanced liver fibrosis (30).
Interestingly, it has been reported that the degradation of this
form of ECM-cross linking can be achieved by MMP-1 (30).
Thus, gene delivery of MMP-1, an interstitial collagenase,
seems to offer several advantages for the treatment of
advanced liver fibrosis, or cirrhosis.
A similar approach using gene delivery of MMP-8,
human neutrophil collagenase, has been reported in animal
models (94). In that experiment, liver fibrosis induced by
CCl4 or bile duct ligation was ameliorated by the adenoviral
gene transfer of MMP-8, and was accompanied by improved
ascites and gastric varices. Meanwhile, adenoviral gene
transfer with human urokinase-type plasminogen activator
(uPA) also reversed experimental rat liver fibrosis inducing
collagenase expression (100). Considering these experimental
data by us and others, gene delivery of interstitial collagenases
seems promising for the treatment of advanced cirrhosis in
humans. However, persistent overexpression of interstitial
collagenases in the liver possibly digests normal architectures
in addition to pathologically deposited ECM. Therefore,
precisely controlled delivery of active interstitial MMPs may
be necessary for developing a treatment for clinical use.
STRATEGIES TO ANTAGONIZE TIMP
For the purpose of antagonizing the excess amounts of
TIMPs in liver fibrosis, some strategies, employing an anti-
TIMP antibody or mutant MMP, have been reported. In the
former report, an anti-TIMP antibody successfully decreased
HSC activation and attenuated fibrosis in a CCl4-induced rat
liver fibrosis (101). In the latter report, mutant MMP was
delivered into a CCl4-induced mouse liver fibrosis (102).
a b
c d
Fig. 3. Liver tissues treated with thioacetamide (200 mg/kg) for 7 weeks were stained with Masson_s trichrome at 2 weeks after the adenoviral
infections (a, b). Liver tissues were collected from control Ad5LacZ-infected (a) or Ad5MMP-1 infected (b) rats. Fibrous tissues were
markedly attenuated with Ad5MMP-1 infection (b). Immunostaining against a-smooth muscle actin (a-SMA) was also performed in the liver
from rats treated with TAA (200 mg/kg) for 7 weeks (c and d). Ad5LacZ-infected (c) and Ad5MMP-1-infected (d) livers at 2 weeks after the
infection are shown. a-SMA-positive area was remarkably reduced with Ad5MMP-1 infection (d). Figures were modified from ref. 46
(Gastroenterology 124: 445–58, 2003).
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TIMPsisapivotalparameterofthedepositionandbreakdown
of the ECM, a catalytically inactive MMP-9 which still binds
TIMP-1 was delivered as a specific antagonistof TIMP-1 in this
study. MMP-9 mutants delivered into CCl4-induced experi-
mental fibrotic livers using an adenoviral vector effectively
suppressed liver fibrosis and inhibited mRNA expression of
type I collagen. Reduced expression of a-SMA, a marker of
activated HSC, was also observed in the livers expressing
MMP-9 mutants. This report has raised the possibility for the
development of a new therapy without adverse side effects
derived from MMP activity exogenously delivered.
APPROACHES TO EFFICIENT AND SAFE DELIVERY
OF MMP GENE
Vectors that have been used for gene therapy are
divided into two broad categories: viral and nonviral vectors.
Viral vectors are derived from viruses with either RNA or
DNA genomes and are represented as both integrating and
nonintegrating vectors (103). RNA virus vectors are derived
from retroviruses, and can be classified into oncoretroviruses,
lentiviruses, and spumaviruses. Among the vectors derived
from DNA viruses, the most prominent are those based on
adenovirus (Ad) and the adeno-associated virus (AAV). As
with any viral vector there are distinct advantages and
disadvantages to its use. Retroviral vectors have shown to
transduce and stably express transgenes for a long period,
although the transduction efficiency is relatively low. Attrac-
tive properties of Ad vectors include their very efficient
transduction of target cells in vitro and in vivo, but immuno-
genicity and toxicity of the vectors could make an obstacle
against clinical use. Among the viral vector systems, AAV
vector, which is derived from nonpathogenic human parvo-
virus, has been suspected as a promising one in treatment of
many kinds of hereditary diseases.
The efficacy of MMP gene delivery using adenoviral
vectors for the treatment of liver fibrosis has been reported as
mentioned above (93,94). However, the clinical use of adeno-
viral vectors is limited by the adverse effects of the virus vector
itself, such as immunogenicity and toxicity as well as the
possible mutagenesis of the cells transfected. Moreover,
expression of MMP genes in the liver for a long period using
viral vectors such as retroviral vectors or AAV vectors may
possibly induce adverse side effect by over-degradation of
ECM in normal architectures. Thus, it is important to create
safe non-viral vectors with significant transduction efficiency
and limited expression for clinical gene therapy of liver fibrosis.
Nonviral vectors should circumvent some of the prob-
lems occurring with viral vectors such as endogeneous virus
recombination, oncogenic effects and unexpected immune
response, and are categorized into two general groups: 1)
naked DNA delivery by a physical method, such as electro-
poration, gene gun, ultrasound and hydrodynamic pressure
and 2) delivery mediated by a chemical carrier such as
cationic polymer and lipid (104). In consideration of selective
MMP gene transfer into the liver, selective injection of naked
DNA into the liver via the portal vein or the hepatic artery,
or gene delivery using a chemical carrier possibly possess
therapeutic potential. From such a view point, an interesting
experiment where plasmid DNA encoding MMP-1 was
delivered to streptozotocin-induced fibrotic kidneys using
cationized gelatin hydrogels has been reported (105). In that
study, in order to facilitate the sustained release of plasmid
DNA, biodegradable hydrogels and microspheres were
formulated from cationized gelatin prepared through amini-
zation. Plasmid DNA was released from the cationized
gelatin hydrogels as a result of hydrogel degradation. The
hydroxylproline content in the murine fibrotic kidneys was
effectively reduced when the gelatin microspheres incorpo-
rating plasmid MMP was administered. A combination of this
kind of strategy and plasmid DNA of catalytically inactive
MMPs may prove useful in treating advanced liver fibrosis in
humans in the future.
SUMMARY
The removal of the causative factors is currently the
most effective intervention in the treatment of liver fibrosis.
Although experimental studies have revealed several targets
to prevent fibrosis progression in rodents (17), whether
complete regression from advanced cirrhosis is possible is
still controversial, especially in humans. Therefore, the
development of more effective and safe therapies against
established liver fibrosis is critically important. In this review,
the authors focused on MMP gene delivery that attempts to
reset the imbalance between too little MMPs and too much
TIMPs in advanced liver fibrosis. The delivery of interstitial
MMPs into advanced liver fibrosis seems rational and is
directed against the excess amount of deposited fibllilar
collagens. More importantly, the data imply that even
transient shifts in the imbalance between MMPs and TIMPs
are sufficient for the resolution of advanced fibrosis, if the
underlying causative stimuli have been successfully removed.
The development of a safe and efficient MMP-delivering
system may prove to be an attractive pharmaceutical target
for the treatment of advanced liver fibrosis and cirrhosis.
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